A világossejtes veserák célzott terápiá ja és molekuláris patológiai alapjai

Translated title of the contribution: Molecular pathology and targeted therapy of clear cell renal cancer

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The golden standard of care for advanced renal cell cancer (RCC) was until now the cytokine therapy with relatively low response rates. Advances of molecular genetics in RCC revealed several molecular targets such as VHL and angiogenic genotype or EGFR in the clear cell variant. Among the novel targeted agents, multiple tyrosine kinase inhibitors were proved to be clinically effective against advanced clear cell renal cancer, changing the standard of care. It is a further question how molecular diagnostics can improve these results by the detection of these targets or gene defects in individual tumors.

Original languageHungarian
Pages (from-to)309-314
Number of pages6
JournalMagyar Onkologia
Volume50
Issue number4
Publication statusPublished - 2006

Fingerprint

Molecular Targeted Therapy
Molecular Pathology
Renal Cell Carcinoma
Standard of Care
Protein-Tyrosine Kinases
Molecular Biology
Genotype
Cytokines
Genes
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A világossejtes veserák célzott terápiá ja és molekuláris patológiai alapjai. / Tímár, J.; Kópper, L.; Bodrogi, I.

In: Magyar Onkologia, Vol. 50, No. 4, 2006, p. 309-314.

Research output: Contribution to journalArticle

@article{5c7433c3be824eeab814a7b24ccf5423,
title = "A vil{\'a}gossejtes veser{\'a}k c{\'e}lzott ter{\'a}pi{\'a} ja {\'e}s molekul{\'a}ris patol{\'o}giai alapjai",
abstract = "The golden standard of care for advanced renal cell cancer (RCC) was until now the cytokine therapy with relatively low response rates. Advances of molecular genetics in RCC revealed several molecular targets such as VHL and angiogenic genotype or EGFR in the clear cell variant. Among the novel targeted agents, multiple tyrosine kinase inhibitors were proved to be clinically effective against advanced clear cell renal cancer, changing the standard of care. It is a further question how molecular diagnostics can improve these results by the detection of these targets or gene defects in individual tumors.",
author = "J. T{\'i}m{\'a}r and L. K{\'o}pper and I. Bodrogi",
year = "2006",
language = "Hungarian",
volume = "50",
pages = "309--314",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "4",

}

TY - JOUR

T1 - A világossejtes veserák célzott terápiá ja és molekuláris patológiai alapjai

AU - Tímár, J.

AU - Kópper, L.

AU - Bodrogi, I.

PY - 2006

Y1 - 2006

N2 - The golden standard of care for advanced renal cell cancer (RCC) was until now the cytokine therapy with relatively low response rates. Advances of molecular genetics in RCC revealed several molecular targets such as VHL and angiogenic genotype or EGFR in the clear cell variant. Among the novel targeted agents, multiple tyrosine kinase inhibitors were proved to be clinically effective against advanced clear cell renal cancer, changing the standard of care. It is a further question how molecular diagnostics can improve these results by the detection of these targets or gene defects in individual tumors.

AB - The golden standard of care for advanced renal cell cancer (RCC) was until now the cytokine therapy with relatively low response rates. Advances of molecular genetics in RCC revealed several molecular targets such as VHL and angiogenic genotype or EGFR in the clear cell variant. Among the novel targeted agents, multiple tyrosine kinase inhibitors were proved to be clinically effective against advanced clear cell renal cancer, changing the standard of care. It is a further question how molecular diagnostics can improve these results by the detection of these targets or gene defects in individual tumors.

UR - http://www.scopus.com/inward/record.url?scp=34248547900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248547900&partnerID=8YFLogxK

M3 - Article

VL - 50

SP - 309

EP - 314

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 4

ER -